On Friday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $27.33 which represents a decrease of $-0.16 or -0.58% from the prior close of $27.49. The stock opened at $27.84 and ...

BridgeBio Pharma Inc (BBIO) stock saw a modest uptick, ending the day at $28.79 which represents a slight increase of $2.13 or 7.99% from the prior close of $26.66. The stock opened at $26.96 and ...

Pipeline and regulatory updates are in focus in the biotech sector. Among these, BridgeBio Pharma, Inc. BBIO gained on ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Legend Biotech (LEGN – Research Report), Disc ...

2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...

Research analysts at HC Wainwright increased their FY2024 earnings estimates for shares of BridgeBio Pharma in a research ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

GET MORE AI-GENERATED SIGNALS: December 02, 2024, 04:48 am ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

Short interest in BridgeBio Pharma Inc (NASDAQ:BBIO) decreased during the last reporting ... are betting on the decline of BridgeBio Pharma's stock. Short interest data is updated every two ...

The candidate has been approved under the brand name Attruby. BBIO stock surged on the news. The FDA approval is based on positive results from the phase III ATTRibute-CM study, in which Attruby ...